Home
Scholarly Works
COST-UTILITY ANALYSIS OF AN ALL-PRETERM INFANT...
Conference

COST-UTILITY ANALYSIS OF AN ALL-PRETERM INFANT IMMUNIZATION WITH NIRSEVIMAB AGAINST RESPIRATORY SYNCYTIAL VIRUS (RSV): ASSOCIATED DISEASE AT THE BRAZILIAN PRIVATE HEALTHCARE SYSTEM

Authors

Watanabe SF; Santoro J; Tolardo A; Safadi M; Stein RT; Falavigna M; Schneider NB; Marmett B; Soudani S

Volume

27

Pagination

pp. S216-S216

Publisher

ELSEVIER SCIENCE INC

Publication Date

December 1, 2024

Conference proceedings

VALUE IN HEALTH

Issue

12

ISSN

1098-3015

Contact the Experts team